Demand in Immunoglobulins Market to 2019

  • 249 views
Uploaded on

The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), …

The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.

The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research’s team of industry experts. Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
249
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications. Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth. Scope Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019 Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology Key drivers and barriers that have a significant impact on the market Coverage of key marketed products, approved indications, and safety and efficacy profiles Coverage of the pipeline molecules in various phases of drug development Competitive profiling of the leading companies: Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma Key M&A activity and licensing agreements between 2012 and mid-2013 in the global immunoglobulin market Overview of the immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products Reasons to Buy Align your product portfolio to the markets with high growth potential Develop market-entry and market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 2. for strong growth Develop key strategic initiatives by understanding the key focus areas of the leading companies Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps table Of Content 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures 2 Immunoglobulins Market To 2019 - Introduction 2.1 Overview 3 Immunoglobulins Market To 2019 - Market Overview 3.1 Revenue 3.2 Annual Cost Of Therapy 3.3 Immunoglobulins Market Drivers And Restraints 3.3.1 Market Drivers 3.3.2 Restraints 4 Immunoglobulins Market To 2019 - Geographical Landscape 4.1 Us 4.1.1 Revenue 4.1.2 Annual Cost Of Therapy 4.2 Top Five European Countries 4.2.1 Revenue 4.2.2 Annual Cost Of Therapy 4.3 Japan 4.3.1 Revenue 4.3.2 Annual Cost Of Therapy 5 Immunoglobulins Market To 2019 - Therapeutic Landscape 5.1 Main Therapeutic Indications 5.1.1 Indicated Conditions For Intravenous Immunoglobulin Usage - Us 5.1.2 Indications For Intravenous Immunoglobulin Usage - Europe 5.1.3 Guidelines For Intravenous Immunoglobulin Usage - Uk Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 3. 5.1.4 Indications For Intravenous Immunoglobulin Usage - Japan 5.2 Revenue Share For The Major Therapeutic Indications 5.3 Primary Immunodeficiency Market 5.3.1 Introduction 5.3.2 Revenue 5.3.3 Annual Cost Of Therapy 5.3.4 Epidemiology 5.3.5 Current Use 5.3.6 Geographical Segmentation 5.4 Guillain-barré Syndrome Market 5.4.1 Introduction 5.4.2 Revenue 5.4.3 Annual Cost Of Therapy 5.4.4 Epidemiology 5.4.5 Current Use For Therapies 5.4.6 Geographical Segmentation 5.5 Chronic Lymphocytic Leukemia Market 5.5.1 Introduction 5.5.2 Revenue 5.5.3 Annual Cost Of Therapy 5.5.4 Epidemiology 5.5.5 Current Use 5.5.6 Geographical Segmentation 5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market 5.6.1 Introduction 5.6.2 Revenue 5.6.3 Annual Cost Of Therapy 5.6.4 Epidemiology 5.6.5 Current Use 5.6.6 Geographical Segmentation 5.7 Myasthenia Gravis Market 5.7.1 Introduction 5.7.2 Revenue 5.7.3 Annual Cost Of Therapy 5.7.4 Epidemiology 5.7.5 Current Use 5.7.6 Geographical Segmentation 5.8 Multifocal Motor Neuropathy Market 5.8.1 Introduction 5.8.2 Revenue 5.8.3 Annual Cost Of Therapy 5.8.4 Epidemiology 5.8.5 Current Use Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 4. 5.8.6 Geographical Segmentation 5.9 Idiopathic Thrombocytopenic Purpura 5.9.1 Introduction 5.9.2 Revenue 5.9.3 Annual Cost Of Therapy 5.9.4 Epidemiology 5.9.5 Current Use 5.9.6 Geographical Segmentation 6 Immunoglobulins Market To 2019 - Profiles Of Marketed Products 6.1 Overview 6.2 Privigen 6.2.1 Overview 6.2.2 Approved Indications 6.2.3 Safety 6.2.4 Efficacy 6.3 Gammagard S/d 6.3.1 Overview 6.3.2 Approved Indications 6.3.3 Safety 6.3.4 Efficacy 6.4 Gammagard Liquid 6.4.1 Overview 6.4.2 Approved Indications 6.4.3 Safety 6.4.4 Efficacy 6.5 Octagam 5% 6.5.1 Overview 6.5.2 Approved Indications 6.5.3 Safety 6.5.4 Efficacy 6.6 Flebogamma 10% Dif 6.6.1 Overview 6.6.2 Approved Indications 6.6.3 Safety 6.6.4 Efficacy 6.7 Gamunex-c 6.7.1 Overview 6.7.2 Approved Indications 6.7.3 Safety 6.7.4 Efficacy 6.8 Gammaplex Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 5. 6.8.1 Overview 6.8.2 Approved Indications 6.8.3 Safety 6.8.4 Efficacy 6.9 Hyqvia 6.9.1 Overview 6.9.2 Approved Indications 6.9.3 Safety 6.9.4 Efficacy 6.10 Bivigam 6.10.1 Overview 6.10.2 Approved Indications 6.10.3 Safety 6.10.4 Efficacy 7 Immunoglobulins Market To 2019 - Pipeline Analysis 7.1 Research And Development Pipeline 7.2 Major Pipeline Product Profiles 7.2.1 Ivig3i Grifols 10% 7.2.2 Ri-002 (ivig) 8 Immunoglobulins Market To 2019 - Competitive Landscape 8.1 Baxter International Inc. 8.1.1 Business Description 8.1.2 Recent Developments 8.2 Biotest Pharmaceuticals 8.2.1 Business Description 8.2.2 Recent Developments 8.3 Bio Products Laboratory Ltd. 8.3.1 Business Description 8.3.2 Recent Developments 8.4 Csl Behring Limited 8.4.1 Business Description 8.4.2 Recent Developments 8.5 Grifols S.a. 8.5.1 Business Description 8.5.2 Recent Developments 8.6 Octapharma Ag 8.6.1 Business Description 8.6.2 Recent Developments Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 6. 9 Immunoglobulins Market To 2019 - M&a And Licensing Deals Landscape 9.1 M&a Deals 9.1.1 Grifols Buys 60% Of Progenika Biopharma 9.1.2 Grifols Acquires 40% Of The Capital Of Biotechnology Firm Vcn Bioscience 9.1.3 Grifols Purchases Three Plasma Donation Centers In The Us From Canada’s Cangene 9.1.4 Baxter Enhances Renal Therapies Portfolio With Acquisition Of Gambro 9.2 R&d Licensing Agreements 9.2.1 Baxter And Onconova Announce European Licensing Agreement For Anti-cancer Compound Rigosertib 9.2.2 Baxter Announces Collaboration With Sanquin To Expand Capacity For Plasma Therapies 9.2.3 Baxter Announces 20 Year Partnership With Hemobras In Brazil 10 Immunoglobulins Market To 2019 - Asia-pacific And China 10.1 India 10.1.1 Overview 10.1.2 Regulatory Landscape 10.1.3 National Institute For Biologicals 10.1.4 Marketed Products 10.1.5 Product Profiles 10.1.6 Company Profiling 10.2 China 10.2.1 Overview 10.2.2 Regulatory Information 10.2.3 Marketed Products 10.2.4 Company Profiling 10.3 Australia 10.3.1 Overview 10.3.2 Regulatory Landscape 10.3.3 Marketed Products 10.3.4 Product Profiles 10.3.5 Company Profiling 11 Global Immunoglobulins Market: Appendix 11.1 Market Definitions 11.2 Abbreviations 11.3 References 11.4 Research Methodology 11.4.1 Coverage 11.4.2 Secondary Research 11.4.3 Primary Research 11.4.4 Expert Panel Validation Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 7. 11.5 Contact Us 11.6 Disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C